Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record.

Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus

Open access
Stone, Gregg. W., Kedhi, Elvin, Kereiakes, Dean J., Parise, Helen, Fahy, Martin, Serruys, Patrick W., Smits, Pieter C.·2011·Circulation

Abstract

Background—: Some (but not all) prior trials have reported differential outcomes after percutaneous coronary intervention with paclitaxel-eluting stents versus stents eluting rapamycin analogs according to the presence of diabetes mellitus. These studies lacked sufficient power to examine individual safety and efficacy end points. Methods and Results—: To determine whether an interaction exists between the presence of diabetes mellitus and treatment with everolimus-eluting stents compared with paclitaxel-eluting stents, we pooled the databases from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) II, SPIRIT III, SPIRIT IV, and A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice (COMPARE) trials in which percutaneous coronary intervention was performed in 6780 patients, 1869 (27.6%) of whom had diabetes mellitus. Patients without diabetes mellitus treated with everolimus-eluting stents compared with paclitaxel-eluting stents had significantly reduced 2-year rates of mortality (1.9% versus 3.1%; P =0.01), myocardial infarction (2.5% versus 5.8%; P <0.0001), stent thrombosis (0.3% versus 2.4%; P <0.0001), and ischemia-driven target lesion revascularization (3.6% versus 6.9%; P <0.0001). In contrast, among patients with diabetes mellitus, there were no significant differences between the 2 stent types in any measured safety or efficacy parameter. Significant interactions were present between diabetic status and stent type for the 2-year end points of myocardial infarction ( P =0.01), stent thrombosis ( P =0.0006), and target lesion revascularization ( P =0.02). Conclusions—: We have identified a substantial interaction between diabetes mellitus and stent type on clinical outcomes after percutaneous coronary intervention. In patients without diabetes mellitus, everolimus-eluting stents compared with paclitaxel-eluting stents resulted in substantial 2-year reductions in death, myocardial infarction, stent thrombosis, and target lesion revascularization, whereas no significant differences in safety or efficacy outcomes were present in diabetic patients. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifiers: NCT00180310 (SPIRIT II), NCT00180479 (SPIRIT III), NCT00307047 (SPIRIT IV), and NCT01016041 (COMPARE).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.031070

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 201

Metadata

Authors
Stone, G. W., Kedhi, E., Kereiakes, D. J., Parise, H., Fahy, M., Serruys, P. W., & Smits, P. C.
Venue
Circulation
Published
2011-08-23
Volume
124
Issue
8
Pages
893-900
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2096237432
Cited by
201
References
0
FWCI
24.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. https://app.cochat.ai/papers/10.1161/circulationaha.111.031070
The paper
Stone, G. W., Kedhi, E., Kereiakes, D. J., Parise, H., Fahy, M., Serruys, P. W., & Smits, P. C. (2011). Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation. https://doi.org/10.1161/circulationaha.111.031070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.